Profile data is unavailable for this security.
About the company
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species.
- Revenue in USD (TTM)53.98bn
- Net income in USD13.91bn
- Incorporated1970
- Employees68.00k
- LocationMerck & Co Inc2000 Galloping Hill RdKENILWORTH 07033-1310United StatesUSA
- Phone+1 (908) 740-4000
- Fax+1 (908) 423-1987
- Websitehttp://www.merck.com/
Mergers & acquisitions
| Acquired company | MRK:NYQ since announced | Transaction value |
|---|---|---|
| Acceleron Pharma Inc | 24.96% | 11.59bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen, Inc. | 26.32bn | 5.72bn | 133.04bn | 24.20k | 24.52 | 145.24 | 14.59 | 5.06 | 10.16 | 10.16 | 46.56 | 1.71 | 0.4324 | 1.55 | 5.54 | 1,087,438.00 | 9.40 | 11.07 | 11.93 | 13.40 | 75.21 | 79.29 | 21.75 | 30.88 | 1.09 | 6.64 | 0.9758 | 49.28 | 2.18 | 2.47 | -18.87 | -5.26 | 1.01 | 11.97 |
| Bristol-Myers Squibb Co | 46.96bn | 6.25bn | 163.30bn | 32.20k | 27.23 | 5.17 | 9.68 | 3.48 | 2.82 | 2.82 | 21.15 | 14.83 | 0.4359 | 4.72 | 6.55 | 1,458,385.00 | 5.82 | 2.67 | 7.16 | 3.29 | 79.62 | 74.18 | 13.35 | 6.54 | 1.23 | 6.75 | 0.587 | 163.84 | 9.09 | 19.01 | 177.58 | 9.43 | -4.35 | 5.22 |
| Merck & Co., Inc. | 53.98bn | 13.91bn | 237.28bn | 68.00k | 17.11 | 5.80 | 13.70 | 4.40 | 5.48 | 5.59 | 21.28 | 16.17 | 0.5466 | 2.56 | 5.98 | 793,794.10 | 14.09 | 7.61 | 18.72 | 10.14 | 71.11 | 70.92 | 25.78 | 16.06 | 1.14 | 42.76 | 0.437 | 86.06 | 17.31 | 4.12 | 173.18 | 25.79 | 22.48 | 7.49 |
| AbbVie Inc | 56.73bn | 12.40bn | 261.59bn | 50.00k | 21.23 | 16.06 | 12.52 | 4.61 | 6.97 | 6.97 | 31.91 | 9.22 | 0.3863 | 5.08 | 5.58 | 1,134,500.00 | 8.50 | 7.46 | 10.90 | 9.46 | 69.78 | 72.03 | 22.01 | 18.11 | 0.708 | 8.54 | 0.8183 | 97.89 | 22.69 | 16.99 | 151.71 | 14.13 | 10.44 | 17.93 |
| Eli Lilly And Co | 29.32bn | 6.13bn | 287.52bn | 35.00k | 44.91 | 30.81 | 37.04 | 9.81 | 6.74 | 6.74 | 32.23 | 9.82 | 0.6255 | 1.99 | 4.92 | 837,794.30 | 13.07 | 11.08 | 17.94 | 15.80 | 74.40 | 77.16 | 20.90 | 20.77 | 0.9765 | 9.83 | 0.6357 | 53.75 | 15.40 | 5.94 | -9.88 | 15.31 | 11.40 | 10.76 |
| Pfizer Inc. | 92.37bn | 25.42bn | 296.70bn | 79.00k | 11.92 | 3.59 | 9.69 | 3.21 | 4.43 | 4.36 | 16.11 | 14.74 | 0.5391 | 3.96 | 8.00 | 1,169,203.00 | 14.86 | 6.62 | 18.43 | 8.25 | 60.45 | 74.04 | 27.56 | 21.32 | 1.13 | 81.49 | 0.3051 | 75.72 | 95.16 | 9.00 | 238.05 | 25.51 | 6.28 | 5.39 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2022 | 205.87m | 8.14% |
| BlackRock Fund Advisorsas of 31 Mar 2022 | 128.16m | 5.07% |
| SSgA Funds Management, Inc.as of 31 Mar 2022 | 118.32m | 4.68% |
| Wellington Management Co. LLPas of 31 Mar 2022 | 45.70m | 1.81% |
| Geode Capital Management LLCas of 31 Mar 2022 | 44.41m | 1.76% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2022 | 30.08m | 1.19% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2022 | 29.74m | 1.18% |
| Massachusetts Financial Services Co.as of 31 Mar 2022 | 28.84m | 1.14% |
| BlackRock Investment Management (UK) Ltd.as of 31 Mar 2022 | 27.31m | 1.08% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 23.79m | 0.94% |
